Monopar Therapeutics Inc (MNPR) — Titan Protect Analysis

MNPR

Monopar Therapeutics Inc

Healthcare · ·

$59.48

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$399M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-18.84

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-15.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$109.00

+83% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 13 analysts covering this stock

About Monopar Therapeutics Inc

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosime

https://www.monopartx.com

Country: United States Employees: 22 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.919

Good returns relative to risk taken

Kelly Fraction

0.2030

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

5.199

Returns exceed worst-case losses — strong risk profile

Annual Return

288.0%

Historical annualised return based on price data

Max Drawdown

-55.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

275

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.50

Significantly more volatile than the market

52W High

$105.00

43% below the year high

52W Low

$29.18

104% above the year low

Avg Volume

182,190

Average daily shares traded — higher means easier to buy and sell

Short Ratio

8.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.93

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.17

Conservative use of debt — low financial risk

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-5,376,986

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-14,984,972

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$130.00

Target Median

$109.00

Target Low

$100.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go